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Abstract
Background Duloxetine and pregabalin are among the most widely used medications in the treatment of patients with fibromy-
algia syndrome (FM).
Objectives To add to the very few lines of evidence that exist on the comparative safety and efficacy of these two medications.
Methods In this open-label randomized clinical trial, outpatient women, who were diagnosed with FM based on American
College of Rheumatology 2010 criteria, and had an age range of 18–65 years old were assigned to either duloxetine 30-60 mg or
pregabalin 75-150 mg per day for 4 weeks. Patients were excluded in cases of having used duloxetine, pregabalin, gabapentin, or
antidepressants within 12 weeks prior to the study, having had a history of comorbid medical conditions that could provoke
chronic pain, or having had comorbid neuropsychiatric disorders, except for major depressive/anxiety disorders. Primary out-
comes were between-group differences in mean score changes from baseline to end point for Widespread Pain Index (WPI) and
Beck Depression Inventory-II. Secondary outcomes were the same statistical estimates, but for Fibromyalgia Impact
Questionnaire-Revised and 12-Item Short Form Survey. Descriptive statistics and independent samples t-test were the main
methods of analysis. (www.irct.ir; IRCT2016030626935N1).
Results Among all the scales, only WPI scores improved with a statistically significant difference between the two treatment arms,
favoring duloxetine (Mean difference in score change − 2.32, 95% CI, −4.46 to− 0.18; p = 0.034; Cohen’s d 0.53 95% CI, 0.04 to
1.02). Drop out rate and cumulative incidence of nauseawas significantly higher in the duloxetine arm compared to the pregabalin arm.
Conclusion This study provides further evidence on higher efficacy of duloxetine compared to pregabalin for the treatment of
pain in patients with fibromyalgia. Future comprehensive pragmatic clinical trials are warranted.
Keywords Clinical trial . Fibromyalgia . Duloxetine . Pregabalin
Introduction
Fibromyalgia syndrome (FM) is a debilitating disorder, de-
fined as chronic widespread musculoskeletal pain in the
absence of identified organic abnormalities, accompanied by
a variety of other symptoms, including but not limited to de-
pression/anxiety, sleep disturbances, fatigue, and cognitive
dysfunction [1]. It is estimated that 1–10% of the general
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population is affected by FM [2], with an approximate
women/men ratio of 9:1 and some clinical differences in
symptomatology between the two genders [3]. Alongside
chronic pain as the main defining feature of patients with
FM, mental symptoms and in particular depressive symptoms
have been prominent enough to provoke a debate on classifi-
cation of FM as a somatoform disorder [4]. According to
previous studies, between 22% and 90% of patients with FM
are affected by major depressive disorder (MDD) [5, 6], and
several overlapping neurobiological findings as well as shared
risk factors are documented for both conditions [5–12].
Treatment of FM remains a major challenge. Several non-
pharmacological approaches as well as more than 40 pharma-
cological compounds have been the subject of research and
clinical practice for the treatment of FM around the world [13,
14], with varied recommendations by international guidelines.
Among the available treatments, duloxetine and pregabalin
are the most widely prescribed medications to patients with
FM and are the only similarly approved drugs by both Food
and Drug Administration and Health Canada organizations
[15]. The two drugs have different mechanisms of action;
duloxetine is a serotonin norepinephrine reuptake inhibitor,
while pregabalin is a gamma amino butyric acid (GABA)
analogue that interacts with voltage-gated calcium channels
in the central nervous system. It also appears that duloxetine
and pregabalin differ in terms of improving FM symptoms,
adverse events, and adherence to treatment [16–18]. To the
best of our knowledge, comparison of these two drugs has
been limited to only a single recent RCT with head-to-head
comparison of the duloxetine and pregabalin [18], and indirect
comparison through systematic reviews/meta-analyses on
placebo-controlled randomized clinical trials (RCTs) of each
drug [16, 17]. Further research on the direct comparison of the
two drugs are prudent to cover the knowledge gaps in differ-
ential patients’ responses to these medications and defining
specific indications for their clinical use.
We aimed at comparing duloxetine and pregabalin for fea-
sibility and efficacy in treating women with FM, using an
RCT design. Improvements in pain and depressive symptoms
were primary outcomes of interest. We also compared the two
drugs for improvements in fibromyalgia overall impact and
quality of life, as well as incidence of adverse events.
Methods
Design and setting
In this open-label randomized clinical trial, patients with FM
were assigned to either Cymbalta® (duloxetine) or Lyrica®
(pregabalin) treatment for 4 weeks in an academic outpatient
rheumatology clinic, Razi Hospital, Guilan University of
Medical Sciences, from May 2016 through March 2017. The
study protocol was approved by the ethics committee of Iran
University of Medical Sciences (code: 25371–109,861) in ac-
cordance with World Medical Association’s code of ethics
(Declaration of Helsinki, revised in Brazil 2013), and regis-
tered at an ICMJE-recognized registry of clinical trials
(IRCT2016030626935N1; www.irct.ir). Written informed
consent was obtained from all patients and if necessary, their
caregivers. Participants were able to withdraw from the study
at any time, and they were clearly informed that their
relationship with the healthcare provider would not be
affected.
Participants
Women diagnosed with FM, based on the American College
of Rheumatology (ACR) 2010 criteria [19], were considered
for study screening. Patients were eligible if they were aged
between 18 and 65 and were willing to participate in the study.
They were excluded if they had a history of taking certain
drugs within a specified period prior to the study enrollment:
duloxetine, pregabalin, gabapentin, or antidepressants within
the last 12 weeks; monoamine oxidase inhibitors within the
last 14 days; muscle relaxants, steroids, opioid analgesics, or
benzodiazepines within the last week; injection of analgesics
to painful areas within the last month. It was also required that
patients: were not pregnant or breast feeding and did not in-
tend to become pregnant during the trial; did not have other
comorbid medical conditions that could provoke chronic pain
such as malignancies, multiple major surgeries, recent trau-
matic injuries, or rheumatologic diseases other than FM; did
not have concurrent neurological or psychiatric disorders ex-
cept anxiety/depressive disorders; did not have occupations
that demanded high level of concentration or alertness; were
not known to have chronic liver diseases, severe renal failure,
or uncontrolled narrow-angle glaucoma; and finally, had no
history of hypersensitivity to trial medications.
Interventions
Patients initially received either duloxetine (30 mg per day) or
pregabalin (75 mg per day). By the time of follow-up clinic
visit at week 1, medications were titrated up to 60 mg
duloxetine, once daily and 75 mg pregabalin, twice daily
(150 mg per day) if the patient was tolerant and no serious
adverse events were observed. During the next 3 weeks, there
were no clinic visits planned; but, patients could come to the
clinic in person for any concern. The study rheumatologist
was available to answer patients’ phone calls, and medication
doses were titrated down in case of new adverse events or
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intolerance. To monitor adherence to treatment, pill counts
were used and were checked with individual patients as well
as their caregivers or companions. In case pill counts exceeded
the expected numbers, or non-adherence was reported by the
patient or caregivers, the issue was explored in detail.
Psychoactive/sedative or pain medications other than trial
medications, or cognitive behavioral therapy were not given
during the trial.
Outcomes and measures
Primary outcomes were defined as the mean difference in
score change for Widespread Pain Index (WPI) (19) and
Beck Depression Inventory-II (BDI-II) [20] at baseline and
week 4, between the two treatment arms. Secondary outcomes
included the mean difference in change of sub-scores and total
score for Fibromyalgia Impact Questionnaire-Revised (FIQ-
R) [21] and 12-Item Short Form Survey (SF-12) [22], as well
as the difference in cumulative incidence of adverse events.
The WPI measures the number of painful areas (score
range = 0–19) on the patient’s body over the last week prior
to the assessment. The BDI-II is composed of 21 questions,
each scored 0–3 (sum = 0–63), with higher scores indicting
more severe depressive symptoms over the past two weeks
prior to the assessment. The FIQ-R contains 3 domains of
Activity Level (9 questions), Overall Impact (2 questions),
and Intensity of Symptoms (10 questions) with each question
scaled from 0 to 10, where higher score indicates higher se-
verity of symptoms. A total score of 0–100 is calculated by
adding up a third of the Activity Level, the raw Overall Impact
score, and one half of the Intensity of Symptoms score. SF-12
measures 8 different concepts of quality of life through 12
questions, which are then aggregated in Physical Component
Summary (PCS) and Mental Component Summary (MCS)
scores, ranging from 0 (lowest level of health) to 100 (highest
level of health), using a specific statistical method [23]. Valid
Persian versions of all scales were available [24–27].
Each patient’s diagnosis with FM was confirmed by one of
the authors (B.G.P), as an expert rheumatologist with more
than 10 years of experience in diagnosis and management of
FM. Questionnaires were mainly completed by the patients.
Two well-trained general practitioners were available to pro-
vide patients with instructions on how to answer the questions,
provide further explanations on specific questions, or provide
assistance with filling the forms.
Safety and adverse events
Each patient underwent a thorough detailed medical history
assessment, clinical examinations, and paraclinical evalua-
tions before treatment assignment. At baseline visit, the
patients and their caregivers were requested to record any
unexpected symptoms or signs during the trial and to report
it at follow-up clinic visits or through telephone calls. Patients
were visited after one week to probe possible adverse events,
using a comprehensive checklist and to provide an opportuni-
ty to ask their questions and discuss their concerns. The rheu-
matologist offered consult to patients on any emergent adverse
events, whether it was a predicted adverse reaction or
unpredicted signs/symptoms reported by the patients, and
made a joint decision with the patient on continuation, discon-
tinuation, or dose adjustment of medication based on severity,
seriousness, and relatedness to the trial medications. The ad-
verse event was considered related to the trial medications if it
emerged after the start of the trial and was known as a
pregabalin/duloxetine-related side effect on the manual pro-
vided by the company or according to the accredited scientific
references).
Sample size
Two sample sizes were calculated separately using WPI and
BDI-II as primary outcomes, and the larger one was chosen
for this study. Expert opinion as well as published clinical
trials of duloxetine and pregabalin [18, 28] were the basis
for estimation of effect sizes and variances. Mean difference
in score change of 2.5 forWPI with a standard deviation of 3.5
was used. Considering a type I error of 5%, and a type II error
of 20%, a primary sample size of 60 (30 patients in each
treatment arm) was calculated.
Randomization, allocation concealment, and blinding
Using computerized random number generation and permuted
blocks of four, participants were randomized to either
duloxetine or pregabalin treatment arm in a 1:1 ratio by an
independent person. Initially, 30 patients were assigned to
each treatment arm, and recruitment was further continued
as patients dropped out of the study before treatment comple-
tion. Once there were 39 patients in each arm, 31 patients in
the pregabalin arm had already completed the trial. From this
point, abstract randomization was continued, and patients
would enter the duloxetine arm if they were supposed to re-
ceive duloxetine based on the randomization number.
Otherwise, if the randomization number indicated that the
patient is supposed to receive the pregabalin, the patient would
not enter the study. This was an open-label clinical trial with
no allocation concealment or blinding. In fact, it was not prac-
tical to blind patients and healthcare providers since both
duloxetine and pregabalin were from international brands,
compliant with World Health Organization on Good
Manufacture Practice.
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Statistical analysis
The IBM SPSS statistics 19.0.0 (IBM Corporations) was used
for all analyses. Analysis was carried out using complete
cases. Shapiro-Wilk test of normality was the basis for decid-
ing on measures of central tendency as well as tests for be-
tween group comparisons. Continuous and categorical data
were reported as mean (standard deviation (SD) or 95% con-
fidence intervals (95%CI)), median (range), or count (%).
Cohen’s d (CI95%) was the choice measure of effect size.
Baseline characteristics (e.g. demographics, history of any
diagnosed comorbid condition), trial medication dosing strat-
egy during the study, change in scale scores and adverse
events were compared using independent samples t-test,
Mann-Whitney U test, or Freeman-Halton extension of
Fisher’s exact test, where appropriate. Degree of freedom
was corrected if assumption of equality of variances was vio-
lated. No correction in p values for multiple testing was con-
sidered, as it could have masked important differences be-
tween the two treatment arms, especially in terms of the com-
parison of mean score changes. In other words, in this clinical
trial of two effective and approved drugs for FM, we were
interested in finding and discussing any difference between
the two drugs. Also, we mainly focused on the patterns of
response to treatment, rather than sole p values in our inter-
pretation of the results.
Results
Participants and baseline characteristics
Out of the 195 screened patients, 99 were randomized to either
duloxetine (n = 60) or pregabalin (n = 39), with 35 and 31
patients meeting the endpoint visit at week 4 in each of the
duloxetine and pregabalin arms, respectively (Fig. 1). A sig-
nificant difference in dropout rate was observed between the
two treatment arms (Duloxetine: N (%) = 25(41.67),
Pregabalin: N (%) = 8(20.51), p value = 0.024), where most
drop outs happened in the first week of the trial. We did not
observe any case of significant non-adherence among those
who completed the study. No significant difference was de-
tected between the two arms in terms of baseline socio-
demographic characteristics, duration of illness, comorbidi-
ties, or medication dosing strategy (Table 1).
Measurement scales
Mean baseline scores were significantly higher in the
pregabalin group compared to the duloxetine group for FIQ-
R activity level subscale (p = 0.037), intensity of symptoms
subscale (p = 0.011), and total score (p = 0.010). Furthermore,
there was a non-significant trend toward lower scores in the
pregabalin arm for baseline mean MCS score. All the scale
Fig. 1 Flow diagram of patients
with fibromyalgia
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scores improved during the trial in both treatment arms
(Table 2). The only scale score that improved with a statisti-
cally significant difference between the two treatment arms
was the WPI score, as a primary outcome that favored
duloxetine with a moderate effect size (Mean difference in
score change − 2.32, 95% CI, −4.46 to − 0.18; p = 0.034;
Cohen’s d 0.53 95% CI, 0.04 to 1.02). No significant differ-
ence was detected for BDI-II, FIQ-R, or SF-12 between the
two treatment arms.
Adverse events
Most adverse events occurred during the first and second
week of the trial (Table 3). Overall incidence of nausea was
significantly higher in the duloxetine arm compared to the
pregabalin arm (Table 3). Although we registered higher inci-
dence of constipation, dry mouth, headache, insomnia, and
hot flashes in the duloxetine arm, no statistical significance
was detected. Furthermore, some patients in the duloxetine
arm experienced blurred vision, decreased appetite, and gen-
eralized weakness, while the patients in the pregabalin arm did
not report these adverse events. In contrast, higher incidence
of dizziness, light headedness, and drowsiness was reported
by patients in the pregabalin arm, with no significant differ-
ence between the two treatment arms. Other adverse events
like palpitation, tremor, decreased sexual desire, and bloating
were scarce and mainly reported in the duloxetine arm.
Discussion
According to primary results, baseline scores were significant-
ly higher in pregabalin group compared to the duloxetine
group for FIQ-R activity level subscale, intensity of symptoms
subscale, and total score (Table 2). Moreover, there was a
trend in baseline mean MCS score toward, with lower scores
in the pregabalin arm compared to the duloxetine arm. In such
situations, it is not recommended that the two treatment arms
be compared in terms of mean score change from baseline to
endpoint, due to the potentially large regression-to-mean ef-
fect, which may introduce bias to p values and distort conclu-
sions. In other words, it is probable that the group with the
higher baseline score shows a greater reduction in scores, or
the group with lower baseline scores demonstrates a greater
increase in scores, depending on the direction of score chang-
es that indicate improvement. However, because there was no
significant difference between the two treatment arms for
score improvement in any of the abovementioned subscales
of FIQ-R or MCS, we decided to report the results for com-
paring mean score changes between duloxetine and
pregabalin arms for all scales, and then focus on patterns of
score changes.
For BDI-II, FIQ-R total score, activity level subscale, and
overall impact subscale, patients in the pregabalin arm had
higher baseline scores compared to the duloxetine arm and
experienced more reduction in scores. Also regarding the
MCS, patients in the pregabalin arm had lower baseline scores
Table 1 Characteristics of
women with fibromyalgia Mean (SD), Median (Range), or Count (%)
Duloxetine (n = 35) Pregabalin (n = 31) P value
Age, years 41.60 (9.02) 43.10 (7.78) 0.476
Marital Status, n% 0.713
• Single 4 (11.43) 4 (12.9)
• Married 31 (88.57) 26 (83.87)
• Divorced/widow 0 (0) 1 (3.23)
Level of Education, n% 0.878
• Primary/Elementary 12 (34.29) 10 (32.26)
• High school diploma 15 (42.86) 15 (48.39)
• University degree 8 (22.86) 6 (19.35)
Occupational Status, n% 0.355
• Householder 31 (88.57) 24 (77.42)
• Employed 4 (11.43) 6 (19.35)
• Student 0 (0) 1 (3.23)
Duration of illness, months 24 (0–240) 36 (0–240) 0.193
Comorbid diseases/disorders, n% 19 (54.29) 22 (70.97) 0.168
Trial medication dose, n% 0.352
• Single dose 4 (11.43) 6 (19.35)
• single➔double 29 (82.86) 21 (67.74)
• single➔double➔single 2 (5.71) 4 (12.9)
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Table 3 Incidence of adverse events in women with fibromyalgia
Number of Patients Number (%) of Patients Overall P value
Adverse event Week 1 Week 2 Week 3 Week 4 Overall, counting each patient once
Nausea Duloxetine
(n = 35)
5 7 2 2 12 (34.29) 0.014
Pregabalin
(n = 31)
2 1 0 0 3 (9.68)
Vomiting Duloxetine
(n = 35)
1 0 0 0 1 (2.86) 0.747
Pregabalin
(n = 31)
0 1 0 0 1 (3.23)
Bloating Duloxetine
(n = 35)
1 1 1 1 1 (2.86) 0.735
Pregabalin
(n = 31)
0 0 0 0 0 (0)
Abdominal pain Duloxetine
(n = 35)
0 1 1 1 1 (2.86) 0.747
Pregabalin
(n = 31)
1 1 0 0 1 (3.23)
Constipation Duloxetine
(n = 35)
7 8 5 5 11 (31.43) 0.062
Pregabalin
(n = 31)
4 3 3 3 4 (12.9)
Dry mouth Duloxetine
(n = 35)
3 5 2 2 6 (17.14) 0.077
Pregabalin
(n = 31)
1 0 0 0 1 (3.23)
Bitter taste in the mouth Duloxetine
(n = 35)
1 1 1 1 1 (2.86) 0.735
Pregabalin
(n = 31)
0 0 0 0 0 (0)
Blurred vision Duloxetine
(n = 35)
1 2 0 0 2 (5.71) 0.355
Pregabalin
(n = 31)
0 0 0 0 0 (0)
Palpitation Duloxetine
(n = 35)
1 0 0 0 1 (2.86) 0.735
Pregabalin
(n = 31)
0 0 0 0 0 (0)
Tremor Duloxetine
(n = 35)
1 1 1 1 1 (2.86) 0.735
Pregabalin
(n = 31)
0 0 0 0 0 (0)
Headache Duloxetine
(n = 35)
3 7 4 3 8 (22.86) 0.063
Pregabalin
(n = 31)
2 1 0 0 2 (6.45)
Dizziness Duloxetine
(n = 35)
4 4 2 2 6 (17.14) 0.207
Pregabalin
(n = 31)
8 2 3 3 10 (32.26)
Lightheadedness Duloxetine
(n = 35)
1 2 1 1 2 (5.71) 0.305
Pregabalin
(n = 31)
4 1 1 1 4 (12.9)
Disequilibrium Duloxetine
(n = 35)
1 1 0 0 1 (2.86) 0.747
Pregabalin
(n = 31)
1 0 0 0 1 (3.23)
Drowsiness Duloxetine
(n = 35)
6 4 2 2 7 (20.00) 0.276
Pregabalin
(n = 31)
7 4 3 2 10 (32.26)
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and experienced a higher increase in scores during the trial.
These patterns are compliant with regression-to-mean effect.
Since we did not detect any significant differences between
the two arms for these measures, we were unable to conclude
that the two treatments were different in improving the scales’
scores, which mainly measure mental symptoms or overall
impact of FM. However, interestingly, WPI and PCS scores
did not follow this pattern. In fact, patients in the duloxetine
arm had lower baseline WPI scores but demonstrated more
reduction in WPI scores compared to the pregabalin arm.
Also, they had higher baseline PCS scores, yet experienced
a higher increase in PCS scores compared with patients who
received pregabalin during the trial. Furthermore, while pa-
tients in the duloxetine arm had lower scores for FIQ-R inten-
sity of symptoms subscale, compared to the pregabalin arm,
both groups demonstrated similar improvements. These later
patterns are opposite to regression-to-mean effect and imply
superiority of duloxetine in improving the scores for these
later three scales, whichmeasure pain and physical symptoms.
Taking all the abovementioned points together, we hypothe-
sized that duloxetine is more effective on physical symptoms,
in particular pain, than pregabalin, but similarly effective on
mental health outcomes, such as depressive symptoms and
mental health quality of life.
To the best of our knowledge, only one recently published
RCT has carried out a head-to-head comparison of duloxetine
and pregabalin for treatment of patients with FM [18].
Consistent with our findings regarding treatment efficacy,
Gilron et al. [18] reported superiority of duloxetine to
pregabalin in pain improvement, but insignificant differences
in mental health or quality of life improvement between the
two treatments. They also reported superiority of pregabalin to
duloxetine in sleep improvement, which was not considered
as a separate outcome in our study. Also, the two previous
large-scale meta-analyses on placebo-controlled randomized
trials of duloxetine, pregabalin, and milnacipran in FM, re-
ported superiority of duloxetine to pregabalin for pain im-
provement [16, 17]. Furthermore, one of these meta-analyses
reported superiority of duloxetine to pregabalin for improving
depression [17], but superiority of pregabalin to duloxetine for
fatigue [17].
Regarding adverse events, we observed less incidence of
nausea in the pregabalin arm, compared to the duloxetine arm.
Similarly, Gilron et al. [18] reported significantly less nausea
and insomnia, and a previous meta-analysis indicated signifi-
cantly less nausea, headache, and diarrhea for pregabalin com-
pared to duloxetine [17]. Consistent with these findings, we
observed a prominently higher rate of consent withdrawal in
the duloxetine arm, compared to the pregabalin arm.
Similarly, results by Gilron et al. and the two meta-analyses
[16–18] tended to favor higher withdrawal due to adverse
events in duloxetine compared with pregabalin; but, did not
conclude statistical significance. As a potential explanation for
variance of withdrawal rate between these studies, we can
Table 3 (continued)
Number of Patients Number (%) of Patients Overall P value
Adverse event Week 1 Week 2 Week 3 Week 4 Overall, counting each patient once
Insomnia Duloxetine
(n = 35)
4 3 1 1 6 (17.14) 0.200
Pregabalin
(n = 31)
1 1 1 0 2 (6.45)
Hot flashes Duloxetine
(n = 35)
4 2 2 2 4 (11.43) 0.080
Pregabalin
(n = 31)
0 0 0 0 0 (0)
Decreased sexual desire Duloxetine
(n = 35)
1 1 1 1 1 (2.86) 0.735
Pregabalin
(n = 31)
0 0 0 0 0 (0)
Decreased appetite Duloxetine
(n = 35)
2 2 1 1 3 (8.57) 0.170
Pregabalin
(n = 31)
0 0 0 0 0 (0)
Generalized weakness Duloxetine
(n = 35)
3 2 2 2 3 (8.57) 0.170
Pregabalin
(n = 31)
0 0 0 0 0 (0)
Urinary Frequency Duloxetine
(n = 35)
1 1 1 1 1 (2.86) 0.735
Pregabalin
(n = 31)
0 0 0 0 0 (0)
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point out the differences in medication dose, interventions for
increasing adherence, concomitant consumption of other med-
ications, as well as the study population of interest.
Concerning methodological aspects, it is noteworthy to
mention that the study by Gilron et al. [18] used a cross-over
design alternating drug assignment between the treatment
arms to reduce inter-subject confounding effects. In addition,
the study was well-blinded. In comparison to that study, we
excluded patients who consumed analgesics from one week
prior to the study to the end of the trial. It was also required
that patients in our study had not received pregabalin or
duloxetine in a long period (3-months) before the study
started. In this manner, we could estimate almost pure effects
of the two discussed medications with no potential drug-drug
interactions or carry-over effects. This issue is especially im-
portant, considering the prominently higher rates of drug-drug
interactions and drug-condition interactions in patients receiv-
ing duloxetine, than those treated with pregabalin [29, 30],
which may in turn affect treatment outcomes and introduce
unwanted bias to the results. Our study provided us with more
powerful means for the comparison of dropout rates between
the two medications, regarding both the sample size and po-
tential order effect. While we could compare a considerable
number of patients receiving either duloxetine or pregabalin
with no order effect from the beginning of the study, the study
by Gilron et al. could account for head-to-head comparison of
only about 10 patients in each of the duloxetine and pregabalin
treatments from the beginning of their study. Interestingly, in
the study by Gilron et al. [18], only 1 patient in the pregabalin
group withdrew in the first period, and no patient in the
pregabalin group dropped out later; but, 3 patients in the
duloxetine group withdrew from the trial during the second
and third periods, which implies potential order effect.
Another difference to be mentioned is that we used ACR
2010 criteria for patient recruitment, but the mentioned study
used ACR 1990.
This study was subject to some limitations. First, the sam-
ple was relatively small and highly selected using several ex-
clusion criteria, which necessitates caution when generalizing
the results to the target population of patients with FM.
Second, the follow-up period was relatively short and there-
fore hindered our assessment for long-term safety and efficacy
of the trial medications. Third, this was an open-label study
with potential risks of bias, in particular observer bias.
However, the fact that we used self-reported WPI and BDI-
II for depression as primary outcomes lessens the concern of
observer bias. Of note, most of the patients in this study were
new-cases of FM with no previous exposure to duloxetine or
pregabalin, which further reduced the risk of bias. Fourth,
there would potentially be loss of some degree of variation
in outcomes due to a high number of dropouts in both treat-
ment arms. In other words, dropouts in clinical trials are a
potential source for enrichment of cases, who are better
responders to treatment. While we did not measure outcome
among dropouts, the fact that they mostly reported adverse
outcomes as the reason for withdrawing their consents lessens
this concern. Fifth, we administered pregabalin up to 150 mg/
day in patients, based on routine standard practice at our clin-
ic. Previous trials and meta-analyses have reported different
outcomes for the 300 and 150 mg doses of pregabalin, regard-
ing safety and efficacy. Sixth, it was not practical to blind
patients and healthcare providers, since any intervention by
drug companies in Iran to make duloxetine and pregabalin
similar in appearance or color would risk their quality.
Future randomized clinical trials for comparing duloxetine
and pregabalin will benefit from longer follow-up periods,
larger sample sizes, and comparison of different medication
doses. Additionally, amongst combinations of different med-
ications used for treatment of patients with FM as a common
practice, duloxetine-pregabalin combination therapy is a rela-
tively new approach that requires further investigation. So far,
only one placebo-controlled clinical trial has compared
duloxetine-pregabalin combination therapy with eachmedica-
tion alone, which yielded promising results regarding both
safety and efficacy [18].
In conclusion, we provided further evidence for higher ef-
ficacy of duloxetine compared with pregabalin monotherapy
to reduce pain in patients with fibromyalgia. Nevertheless,
adverse events, adherence to treatment, and drug-drug inter-
actions should be considered when deciding to tailor
duloxetine or pregabalin to an individual patient. Future com-
prehensive pragmatic clinical trials are warranted to illuminate
comparative effectiveness, safety, and healthcare costs of pa-
tients with fibromyalgia, who are treated with duloxetine and
pregabalin, or a combination of the two.
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